Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CHUbVi

Financiado

Cerrado

Ubiquitin Chains in Viral Infections

Viruses such as Influenza A (IAV) and others remain one of the greatest threats to human health and society. Despite their danger and widespread prevalence, the molecular mechanisms of how they infect mammalian hosts and evade the... ver más

28/02/2026

FMI

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL R... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-09

ERC-2019-SyG: ERC Synergy Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

FMI

2.70M€ | Lider

LOGROTEX

232.87K€ | Participante

UNIVERSITY OF BRISTOL

1.93M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

UBIFLU Ubiquitin Signalling Pathways Required for Influenza Virus R... 100K€ Cerrado

ER and Infection ER Function In Virus Infection 183K€ Cerrado

FLU-POLII Association between influenza virus RNA polymerase and the t... 222K€ Cerrado

LOFlu Controlling Influenza A Virus Liquid Organelles 3M€ Cerrado

PGC2018-099341-B-I00 CARACTERIZACION DE LA DINAMICA TRANSCRIPCIONAL DEL VIRUS DE... 191K€ Cerrado

PID2021-126510NB-I00 PROTEINAS TIPO UBIQUITINA EN LA INTERACCION VIRUS-CELULA 206K€ Cerrado

Duración del proyecto: 74 meses Fecha Inicio: 2019-12-09
Fecha Fin: 2026-02-28

Líder del proyecto

FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL R... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Viruses such as Influenza A (IAV) and others remain one of the greatest threats to human health and society. Despite their danger and widespread prevalence, the molecular mechanisms of how they infect mammalian hosts and evade the immune system remains poorly understood. Recent studies from our team implicate two common proteins – HDAC6 and unanchored ubiquitin chains – in host cells as key mediators of viral entry via the aggresome processing pathway. This discovery offers a new line of investigation for understanding and preventing viral infections. By identifying the pathways and interactions involved in this infection process, we will provide new molecular targets for the development of broad-spectrum antiviral compounds. Multidisciplinary studies by a team consisting of a molecular biologist, a virologist, and a chemical biologist will use a diverse set of tools to validate these pathways and gain fundamental knowledge about their regulation. To achieve this, detailed studies on the exact nature of the ubiquitin chains needed to activate HDAC6 will allow the development of biochemical and cellular assays of Influenza A infection and enable the determination of the precise mechanism and the downstream cellular pathways necessary for viral infection. The chemical synthesis of labeled ubiquitin chains will support detailed structural studies and a clear understanding of how they are formed and packaged into infectious viral particles. The strong possibility that numerous other virus types also utilize this pathway will be tested with life-threatening agents of current concern including Zika, Dengue, Ebola, and MERS viruses. By demonstrating – with both biological approaches and small molecule compounds – that blocking these cellular processes in cells and animal models reduces viral infection, this project will provide a wealth a novel insights and the basis for the development of a new generation of anti-viral therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores